Aerie Pharmaceuticals (NASDAQ:AERI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aerie reported mixed results for the fourth quarter. Though earnings missed estimates, Rhopressa sales comfortably beat estimates and doubled sequentially. The solid uptake in prescription volumes should propel Rhopressa sales further, as glaucoma is one of the largest segments in the global ophthalmic market. The FDA approval of its second candidate, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan has further boosted the company’s portfolio. Shares have underperformed the industry in the past six months. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta among others.”
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
PlayAGS (NYSE:AGS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $29.00 price target on the stock. According to Zacks, “PlayAGS, Inc. is a designer and supplier of electronic gaming machines and other products and services for the gaming industry. The company’s product line-up includes Class III EGMs for commercial and Native American casinos, video bingo machines for select international markets, table game products and interactive social casino products. PlayAGS, Inc. is headquartered in Las Vegas, Nevada. “
Amalgamated Bank (NASDAQ:AMAL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Amalgamated Bank provides personal and commercial banking products and services to working families, unions, commercial real estate industries, healthcare markets, institutional investors, law firms, non-profits and political organizations. The company offers checking, savings, certificates of deposit, money market and individual retirement accounts; home equity lines of credit options, mortgages and personal loans and lines of credit options and commercial loans. It also provides services for online banking and bill pay, organization banking, investment management, small business banking, treasury management, commercial banking and real estate aspects. The company’s operates primarily in Manhattan, Roosevelt Island, Bronx, Brooklyn, and Queens, New York; Pasadena, California; and Washington, District Of Columbia. Amalgamated Bank is based in NEW YORK. “
Apple Hospitality REIT (NYSE:APLE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Apple Hospitality REIT, Inc. is a real estate investment trust. Its portfolio consists of hotels, guest rooms and resorts. The company operates primarily in the United States. Apple Hospitality REIT, Inc. is headquarted in Richmond, VA. “
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $2.25 price target on the stock. According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Arlo Technologies (NYSE:ARLO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arlo Technologies, Inc. product design, wireless connectivity, cloud infrastructure and cutting-edge AI capabilities focuses on delivering a seamless, smart home experience. The company’s cloud-based platform provides users with visibility, insight and a powerful means to help protect and connect in real-time. Its connected devices, including wire-free smart Wi-Fi and LTE-enabled cameras, advanced baby monitors and smart security lights. Arlo Technologies, Inc. is based in San Jose, United States. “
Broadcom (NASDAQ:AVGO) had its buy rating reissued by analysts at Rosenblatt Securities. The firm currently has a $350.00 price target on the stock. The analysts wrote, “We rate AVGO a Buy and maintain our $350 price target. Solid overall January quarter results and the reiteration of FY19 sales of $24.5 billion demonstrates the company’s superior business model able to withstand industry gyrations and uncertainty. Investors may take pause on declining gross margins for the rest of the year, but we would position as mix related on conservatism on the CA part of the business. Relatively strong semiconductor business trends are being driven by networking data center Tomahawk3 switches (offsetting industry compute and storage inventory issues) and stabilization in wired/broadband. Wireless is viewed as having a strong back half of the year on strong dollar content expansion (FBAR content and reclaiming a lost socket from last year).””
Broadcom (NASDAQ:AVGO) had its hold rating reiterated by analysts at Wells Fargo & Co.
Basf (ETR:BAS) was given a €78.00 ($90.70) target price by analysts at Credit Suisse Group AG. The firm currently has a buy rating on the stock.
Eversource Energy (NYSE:ES) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Eversource Energy’s shares have underperformed its industry in the past three months. Ongoing delay in the approval of Northern Pass project, its dependence on third party, stringent regulation, and underperformance of its transmission and distribution system due to breakdown are concerns. Refusal by Connecticut Water will hurt its plans to expand water business through acquisition. However, Eversource’s investments in renewable energy generation, expansion of transmission and distribution systems will help it to provide reliable services to its customers. Start of the new water segment will diversify the source of its revenues. Its regulated investment plans will help boost earnings per share by 5-7% over the 2019-2023 time frame from the 2018 level.”
Restoration Robotics (NASDAQ:HAIR) was downgraded by analysts at Maxim Group from a buy rating to a hold rating.
Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Inovio incurred wider-than-expected loss in Q4. Moreover, revenues missed estimates. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have underperformed the industry so far this year.”
Kloeckner & Co SE (ETR:KCO) was given a €8.00 ($9.30) price target by analysts at Kepler Capital Markets. The firm currently has a neutral rating on the stock.
Lanxess (ETR:LXS) was given a €54.00 ($62.79) price target by analysts at Credit Suisse Group AG. The firm currently has a neutral rating on the stock.
Lanxess (ETR:LXS) was given a €52.00 ($60.47) target price by analysts at Nord/LB. The firm currently has a neutral rating on the stock.
ArcelorMittal (AMS:MT) was given a €30.00 ($34.88) price target by analysts at Kepler Capital Markets. The firm currently has a buy rating on the stock.
Nextera Energy Partners (NYSE:NEP) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “If prices of natural gas continue to fluctuate, it will hurt NextEra Energy Partners as the demand for new pipeline projects will be adversely impacted. Stringent rules and regulations, along with dependence on a limited group of customers to generate earnings are headwinds. However, NextEra Energy Partners’ units have outperformed its industry in the past 12 months. NextEra Energy Partners’ renewable assets in the United States have long-term contracts and enjoy the benefits of government initiatives to produce higher volume of electricity from clean sources. NextEra Energy Partners acquisition of nearly 1.4GW of renewable assets from Energy Resources diversified the partnership’s existing portfolio of renewable assets. The decision to sell its Canadian assets and focus on high quality domestic renewable assets is expected to be accretive to long-term goal.”
Prestige Consumer Healthcare (NYSE:PBH) had its buy rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $97.00 price target on the stock.
K&S (ETR:SDF) was given a €18.50 ($21.51) target price by analysts at Credit Suisse Group AG. The firm currently has a neutral rating on the stock.
Selecta Biosciences (NASDAQ:SELB) had its buy rating reiterated by analysts at Stifel Nicolaus. They currently have a $7.00 price target on the stock. The analysts wrote, “We are reiterating our Buy rating and $7 target price after SELB reported its 4Q18 financial and business update. While we believe SELB’s 1Q19 capital raise addressed some of the near-term headwinds for the stock and should allow the company to further develop its lead program, SEL-212, as a treatment for chronic severe gout, we do think the company must execute well in order to achieve its communicated timelines, which appear somewhat aggressive. As we published recently, the design of the H2H study (SEL-212 vs. Krystexxa) and the fact Krystexxa is being used as monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, even if results are positive. With that said, we remain encouraged after our discussion with management today in which it indicated securing a partnership for its ImmTOR platform remains a priority this year.””
Salzgitter (ETR:SZG) was given a €22.00 ($25.58) target price by analysts at Kepler Capital Markets. The firm currently has a sell rating on the stock.
ThyssenKrupp (FRA:TKA) was given a €22.00 ($25.58) price target by analysts at Kepler Capital Markets. The firm currently has a buy rating on the stock.
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.